ArticleActa diabetologica2025
Case series of a hybrid closed loop therapy system used in pregnancy.
Article in Acta diabetologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimizing Automated Insulin Delivery Systems for Pregnancy.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Automated Insulin Delivery for Type 1 Diabetes: Present and Future.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe effectiveness of Hybrid Closed-Loop (HCL) therapy is rarely studied in type 1 diabetes (T1D) pregnancies.
methodsT1D pregnancies (n = 15) managed off-label during gestation using a commercially available HCL system, Tandem Control IQ, were retrospectively reviewed for baseline characteristics, continuous glucose monitoring (CGM), insulin pump use, insulin doses, and gestational health outcomes. Analyses for unadjusted descriptive statistics of baseline characteristics, glycemic parameters, and gestational health outcomes were performed (mean ± standard deviation (SD) or median with interquartile range (IQR) for continuous variables). Control IQ was used prior to pregnancy by 12 of the 15 cases, with 3 initiating use during gestation.
resultsOn average, targets were met for pregnancy-specific Time-In-Range (psTIR, 63-140 mg/dL for > 70%) during most of gestation, pregnancy-specific Time-Below-Range (psTBR, < 63 mg/dL for < 4%) throughout gestation, and pregnancy-specific Time-Above-Range (psTAR, > 140 mg/dL for < 25%) from 10- to 17-week gestation. Targets for non-pregnancy TIR (70-180 mg/dL), TAR (> 140 mg/dL), and TBR (< 70 mg/dL) were met preconception and post-partum. Glycemic metrics improved after the first pregnancy visit wherein assistive techniques were applied for off-label use of this HCL system. Gestational health outcomes were as anticipated for T1D pregnancies.
conclusionsTandem Control IQ HCL therapy used with assistive techniques in 15 T1D pregnancies was associated with improved glycemic levels from the first clinic visit onward.
Indexed as
Identifiers
39945888What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.